According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
NEIAFMR to be developed as the national hub for folk medicine
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
US FDA approval based on NEURO-TTRansform Phase III results
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Subscribe To Our Newsletter & Stay Updated
